Latest Vaccination News
Progress so far
Over three quarters of all priority groups have now received their COVID-19 vaccination in Chichester
More than 40,000 vaccinations have been delivered across the GP practices in and around Chichester.
80.7% of all patients in the nationally set eligibility groups have now received their vaccination – that includes those aged 50 and over, those clinically extremely vulnerable and those who have underlying health conditions.
Thanks continue to all of the teams across the two vaccination services including the many volunteers who are providing this vaccination to the most vulnerable patients.
If you have any questions about the vaccination programme please email email@example.com Please note this cannot be used to arrange appointments.
What is happening now?
Over the coming weeks first dose appointments will continue for those in these groups at both Tangmere and Selsey.
There have been concerns that Tangmere will close this month but that is not the case.
In recent weeks people identified by their age have been invited to use the national booking service to arrange an appointment at one of the mass vaccination centres (eg Westgate) or pharmacy led services.
Patients with an underlying health condition eg diabetes and learning disabilities have been the focus of our service, with more appointments taking place over the coming days and weeks.
If anyone has an underlying health condition and has not been contacted, please email the service team on firstname.lastname@example.org with your name, date of birth and contact number so they can arrange your appointment.
We have now started inviting patients for their second vaccination and are doing so strictly in the order that patients received their first vaccination. If you received your vaccination at Tangmere or Selsey, you must return to those centres for your second vaccination, the Westgate Centre will not be able to provide you with this.
If you received your first vaccination before:
22 January 2021
and have not yet been contacted to book your second vaccination, please telephone:
0333 370 4111, Monday to Friday, 8.30am-12.30pm.
Please do NOT call this number if you received your vaccination after that date – your turn will come.
The Latest Figures
COVID Vaccinations - Updated 21st March 2021
Percentage of Patients given first COVID Vaccination
Chichester Alliance of Medical Practices
UK National Average
94.7% of ChAMP patients aged over 60 years have been vaccinated
49.6% of ChAMP patients aged 50-59 years have been vaccinated
88.0% of ChAMP patients aged 16-64 years with a risk condition have been vaccinated
The Eligible Cohorts
The eligible cohorts are listed below. Cohorts 1 – 7 and 9 are currently being vaccinated at Selsey and Tangmere (highlighted in blue):
Priority 1: Residents in a care home for older adults and staff working in care homes for older adults.
Priority 2: All those 80 years of age and over, frontline health and social care workers.
Priority 3: All those 75 years of age and over.
Priority 4: All those 70 years of age and over, those clinical extremely vulnerable individuals over 16 years old.
Priority 5: All those 65 years of age and over.
Priority 6: Adults aged 16 to 65 years in an at-risk group.
Priority 7: All those 60 years of age and over.
Priority 8: All those 55 years of age and over.
Priority 9: All those 50 years of age and over.
We have tried contacting all patients in Cohorts 1 – 7 above, and we are beginning to book Cohort 9. If you are in one of these cohorts and still wanting the vaccination, please email your name and telephone contact numbers to email@example.com or telephone 0333 370 4111, Monday to Friday, 8.30am-12.30pm.
Please advise us if we should use a different telephone number to contact you, if you are temporarily living away from your permanent home but remain within the wider Chichester area. If you are living temporarily in a different part of the country, please contact a local practice for their arrangements.
Further updates on the COVID Vaccination will be provided on this news page as they become available.
Reassurance about the use of Oxford Astra Zeneca vaccine
We are aware that there are concerns being raised by members of the public following reports of blood clots in relation to the Oxford AstraZeneca COVID-19 vaccine and, most recently, the Irish authorities’ action to temporarily suspend this vaccine.
This briefing helps to provide key messages to be able to respond to any concerns and to encourage uptake of the vaccination.
- We are aware that there have been reports about the Oxford AstraZeneca COVID-19 vaccine, however the UK regulators are clear that the vaccine should continue to be used and people should attend their appointments
- The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines and is responsible for the regulation of the vaccines being offered as part of this programme and they have reviewed all of the evidence.
- Their statement says that the available evidence does not suggest that blood clots in veins (venous thromboembolism) are caused by COVID-19 Vaccine AstraZeneca and people should go to their appointments as this is vital protection from COVID-19.
- This follows a detailed review of reported cases as well as data from hospital admissions and GP records.
- There is no evidence that blood clots in the veins are occurring more often in people who have received the vaccine than in people who have not, for either vaccine
- The MHRA’s advice remains that the benefits of the vaccine against COVID-19, with its associated risk of hospitalisation and death, continue to outweigh the risks of potential side effects.
- People should go and get their COVID-19 vaccine when asked to do so.
- Please continue to attend your appointment – this is really important protection for you
- Please work with us to book your appointment - this is really important protection for you.
Priority Group 6 - Clinical risk groups 16 years of age and over who should receive COVID-19 immunisation
|Chronic respiratory disease||Individuals with a severe lung condition, including those with asthma that requires continuous or repeated use of systemic steroids or with previous exacerbations requiring hospital admission, and chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema; bronchiectasis, cystic fibrosis, interstitial lung fibrosis, pneumoconiosis and bronchopulmonary dysplasia (BPD).|
|Chronic heart disease and vascular disease||Congenital heart disease, hypertension with cardiac complications, chronic heart failure, individuals requiring regular medication and/or follow-up for ischaemic heart disease. This includes individuals with atrial fibrillation, peripheral vascular disease or a history of venous thromboembolism.|
|Chronic kidney disease||Chronic kidney disease at stage 3, 4 or 5, chronic kidney failure, nephrotic syndrome, kidney transplantation.|
|Chronic liver disease||Cirrhosis, biliary atresia, chronic hepatitis.|
|Chronic neurological disease||l disease Stroke, transient ischaemic attack (TIA). Conditions in which respiratory function may be compromised due to neurological disease (e.g. polio syndrome sufferers). This includes individuals with cerebral palsy, severe or profound learning disabilities, Down’s Syndrome, multiple sclerosis, epilepsy, dementia, Parkinson’s disease, motor neurone disease and related or similar conditions; or hereditary and degenerative disease of the nervous system or muscles; or severe neurological disability.|
|Diabetes mellitus||Any diabetes, including diet-controlled diabetes.|
|Immunosuppression||Immunosuppression due to disease or treatment, including patients undergoing chemotherapy leading to immunosuppression, patients undergoing radical radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients, HIV infection at all stages, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID). Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil. Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day for adults. Anyone with a history of haematological malignancy, including leukaemia, lymphoma, and myeloma and those with systemic lupus erythematosus and rheumatoid arthritis, and psoriasis who may require long-term immunosuppressive treatments. Most of the more severely immunosuppressed individuals in this group should already be flagged as CEV. Individuals who are not yet on the CEV list but who are about to receive highly immunosuppressive interventions or those whose level of immunosuppression is about to increase may be therefore be offered vaccine alongside the CEV group, if therapy can be safely delayed or there is sufficient time (ideally two weeks) before therapy commences. Some immunosuppressed patients may have a suboptimal immunological response to the vaccine (see Immunosuppression and HIV).|
|Asplenia or dysfunction of the spleen||This also includes conditions that may lead to splenic dysfunction, such as homozygous sickle cell disease, thalassemia major and coeliac syndrome.|
|Morbid obesity||Adults with a Body Mass Index ≥40 kg/m².|
|Severe mental illness||Individuals with schizophrenia or bipolar disorder, or any mental illness that causes severe functional impairment.|
|Adult carers||Those who are eligible for a carer’s allowance, or those who are the sole or primary carer of an elderly or disabled person who is at increased risk of COVID-19 mortality and therefore clinically vulnerable.|
|Younger adults in long-stay nursing and residential care settings||Many younger adults in residential care settings will be eligible for vaccination because they fall into one of the clinical risk groups above (for example learning disabilities). Given the likely high risk of exposure in these settings, where a high proportion of the population would be considered eligible, vaccination of the whole resident population is recommended. Younger residents in care homes for the elderly will be at high risk of exposure, and although they may be at lower risk of mortality than older residents should not be excluded from vaccination programmes|
Flu Vaccine and COVID Vaccine
If you have just had a flu vaccination (or any other vaccination) and are called for your COVID vaccine appointment, please tell the person making the booking so they can time your appointment to give you the greatest benefit.
It is recommended that there should be a gap of at least seven days between another vaccination and either dose of the Pfizer/BioNTech COVID-19 vaccination (which is given in two doses, 12 weeks apart).
The suggested seven-day gap between the flu vaccine and COVID-19 vaccine is recommended because:
- It is possible that the COVID vaccine may be less effective if administered very close to another vaccine.
- If patients experience any side-effects, it will be easier to identify which vaccine caused them.
If patients do come for their COVID-19 vaccination within seven days of receiving their flu vaccination, in the majority of cases, vaccination with the COVID-19 vaccine can proceed, to avoid any further delay in protection, but you should be aware of the drawbacks.
Community Transport Assistance
An amazing group of volunteers have coordinated a new service to help those who are unable to arrange their own transport to the vaccination centre.
They are now in a position to offer some assistance with transport to and from The Selsey Centre for Covid Vaccinations.
Places are limited and it is therefore vital that these places are utilised only by those people who are unable to make their own way (including those who have use of a mobility scooter) or who are not able to gain lifts from friends, relatives or neighbours.
Transport will be provided by volunteer drivers in a Covid safe environment.
If you would like to book a place, please contact Julie on 07590 060 234 only once your appointment time and place has been confirmed.
PLEASE NOTE THAT THIS SERVICE IS NOT ORGANISED BY THE PRACTICE AND WE ARE NOT ABLE TO ANSWER QUESTIONS OR MAKE BOOKINGS.